The "Undruggable" Cancer Protein Just Met Its Match — And 8 Other Wins Worth Knowing

One patient arrived at Columbia University with metastatic pancreatic cancer — the kind of diagnosis that typically comes with a grim countdown measured in months. Today, more than three years later, he still shows no trace of the disease. No viable cancer cells. No further treatment. Just a scan that comes back stubbornly, beautifully clean.

That single "pathologic complete response" is one of the most remarkable outcomes in a wave of new cancer research that stretches from Umeå to Sydney, from the molecular machinery of a single protein to the economics of a hospital bill.

Unlocking the "undruggable"

For decades, the protein c-Myc has haunted cancer researchers. Roughly 70% of cancers overexpress it, and it drives tumor growth relentlessly. Yet it's been called "undruggable" — a protein with no obvious binding sites where small molecules can attach and block it.

Now, as researchers at Umeå University report in the Proceedings of the National Academy of Sciences, Robin Fåhraeus and his team have found a workaround: instead of attacking the protein directly, they target the genetic instructions that produce it. Same outcome, different door. Tumor cell growth slows.

It's a reminder that the biggest breakthroughs often come from refusing to accept that a door is locked.

A bacterial clue hiding in plain sight

Across the ocean, at the University of Illinois Urbana-Champaign and Mie University in Japan, scientists uncovered something stranger. A bacterial protein fragment called corisin drives pulmonary fibrosis by infiltrating cells' quality-control systems — and when they blocked it with an antibody, the damage impeded. The findings, published in Nature Communications, move corisin from "intriguing bacterial peptide" to "causally supported driver of disease," in the words of professor Isaac Cann.

"Understanding how a disease develops is the key to discovering better treatments," Cann said. Sometimes the key isn't found in oncology — it's found in microbiology.

Two unlikely allies against pancreatic cancer

Back in the pancreatic cancer arena, two separate teams are testing unconventional weapons. At Cedars-Sinai, investigators added a clinical version of the dietary supplement L-glutamine to standard chemotherapy in an early-phase trial published in Nature Cancer. First author Jun Gong noted the grim baseline: current treatment for stage 4 pancreatic cancer offers eight to 13 months. Adding L-glutamine improved survival — the first trial to evaluate it this way in humans.

Meanwhile, at Columbia, Gulam Manji's team reported encouraging results in Nature Communications using a combination therapy that appears to overcome pancreatic cancer's notorious resistance to immunotherapy. "We desperately need new tools in our arsenal," Manji said. That clean-scan patient — cancer-free for more than two years — is the proof of concept.

75 years, 25.8 million life-years

Zoom out, and the wins stack up. An analysis led by Blood Cancer United, published in Blood Advances, found that treatment advances in major blood cancers have saved more than 25.8 million years of life in the United States since 1949, when the first chemotherapies emerged. Blood cancers represent about 10% of all U.S. cancer diagnoses, with more than 192,000 people expected to be diagnosed this year.

But the analysis carries an honest caveat: the gains haven't reached everyone equally. Survival progress remains limited for people with acute myeloid leukemia and for Black individuals across most major blood cancer types. This is progress with unfinished business.

Small molecules, big arithmetic

The economics of hope matter too. A study from UCLA Health's Jonsson Comprehensive Cancer Center, published in JAMA Oncology, found that patients who used lower-cost biosimilar versions of biologic drugs saw average monthly costs drop by $3,820 for insurers and $39.50 out of pocket compared with brand-name versions. Since financial hardship is linked to nonadherence and worse outcomes, cheaper effective drugs aren't just a cost-saving measure — they're a survival strategy.

Meanwhile, at the University of Sydney, a 1,491-patient randomized trial in BMJ Open showed that physiotherapist-led care in emergency departments slashed waiting and treatment times for musculoskeletal conditions — the over 1.3 million annual visits that crowd already-stretched hospitals. Same care, different gatekeeper, better flow.

What this means for you

None of these stories is a cure-all. But together they trace a pattern: progress is rarely one thunderclap — it's a thousand small, clever turns. An RNA-based detour around an undruggable protein. A supplement that tilts chemotherapy in the right direction. A biosimilar that trims a bill. A physiotherapist who frees up an ER bed.

Each one is someone refusing to accept the room as it's lit. And across labs from Umeå to Lund to Sydney, that refusal keeps compounding. The next clean scan could be anyone's.